Literature DB >> 2972244

Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma.

J H Finke1, R Tubbs, B Connelly, E Pontes, J Montie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2972244     DOI： 10.1111/j.1749-6632.1988.tb36356.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  10 in total

1.  The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.

Authors:  G G Steger; M F Gnant; M P Djavanmard; R M Mader; R Jakesz; W Pierce; J B deKernion; R Figlin; A Belldegrun
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

3.  Bcl-2 immunoreactivity in salivary gland neoplasms is unrelated to the expression of mRNA for natural killer cell stimulatory cytokines interleukin (IL)-2 and IL-12.

Authors:  H B Hellquist; M G Karlsson; G Viale; C Karlsson; A Davidsson; P Dell'Orto; J Olofsson
Journal:  Virchows Arch       Date:  1996-10       Impact factor: 4.064

4.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

5.  Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.

Authors:  H Inoue; M Adachi; N Karimine; S Arinaga; H Ueo; D Korenaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.

Authors:  Nina Chi Sabins; Jennifer L Taylor; Kellsye P L Fabian; Leonard J Appleman; Jodi K Maranchie; Donna Beer Stolz; Walter J Storkus
Journal:  Mol Ther       Date:  2013-07-30       Impact factor: 11.454

7.  Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma.

Authors:  R M Bukowski; J Young; G Goodman; F Meyers; B F Issell; J S Sergi; D McLain; G Fyfe; J Finke
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

Review 8.  A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated?

Authors:  Matthew M Cooney; Scot C Remick; Nicholas J Vogelzang
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

9.  The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.

Authors:  G G Steger; R Kaboo; J B deKernion; R Figlin; A Belldegrun
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

Review 10.  Update on vaccine development for renal cell cancer.

Authors:  Nina Chi; Jodi K Maranchie; Leonard J Appleman; Walter J Storkus
Journal:  Open Access J Urol       Date:  2010-08-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.